We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The first trial in multi-district litigation over claims the antipsychotic drug Abilify caused compulsive behavior must proceed in June, a federal judge has ruled. Read More
Doctors are five times more likely to prescribe a brand name drug if they receive payments from a pharmaceutical company for that drug, and the likelihood increases to 14.5 times for specific opioids, according to a new analysis from CareDash. Read More
The lawsuit cites examples, including a November 2014 incident when a plaintiff paid the pharmacy a $20 copay for amlodipine besylate, a 1,043 percent markup from the $1.75 paid to the pharmacist. Read More
A federal judge refused a motion by CIGNA to dismiss a class-action lawsuit alleging it artificially inflated the cost of prescription drugs. Read More
Criminal and financial penalties against pharmaceutical manufacturers continued a downward trend in the past two years and financial penalties for unlawful promotion dropped dramatically since 2013, according to Public Citizen, in a new analysis of federal and state settlements from 1991 to 2017. Read More
Judge John Z. Lee of the Northern District of Illinois wrote that the higher prices Walgreens reported to insurers constituted false factual statements. Read More
Pay-for-delay deals between branded and generic drugmakers in the European Union continued to decline in 2016, according to the latest update from the European Commission. Read More
Generic manufacturer Impax Laboratories agreed to pay $35 million to settle pay-for-delay lawsuits brought by a class of direct purchasers of the acne medication Solodyn (minocycline), sold by Medicis Pharmaceutical, a unit of Valeant. Read More